Department of Public Health Sciences, Clemson University, Clemson, SC 29634, USA.
Center for Public Health Modeling and Response, Clemson University, Clemson, SC 29634, USA.
Int J Environ Res Public Health. 2023 May 9;20(10):5766. doi: 10.3390/ijerph20105766.
There is growing concern about the over-prescription of opioids and the risks of long-term use. This study examined the relationship between initial need (pre-operative, post-operative, and discharge pain) and dosage of opioids in the first prescription after surgery with continued opioid use through opioid refills over 12 months, while considering patient-level characteristics. A total of 9262 opioid-naïve patients underwent elective surgery, 7219 of whom were prescribed opioids following surgery. The results showed that 17% of patients received at least one opioid refill within one year post-surgery. Higher initial opioid doses, measured in morphine milligram equivalent (MME), were associated with a greater likelihood of continued use. Patients receiving a dose greater than 90 MME were 1.57 times more likely to receive a refill compared to those receiving less than 90 MME (95% confidence interval: 1.30-1.90, < 0.001). Additionally, patients who experienced pain before or after surgery were more likely to receive opioid refills. Those experiencing moderate or severe pain were 1.66 times more likely to receive a refill (95% confidence interval: 1.45-1.91, < 0.001). The findings highlight the need to consider surgery-related factors when prescribing opioids and the importance of developing strategies to balance the optimization of pain management with the risk of opioid-related harms.
人们越来越关注阿片类药物的过度处方和长期使用的风险。本研究通过考虑患者特征,考察了初始需求(手术前、手术后和出院时的疼痛)与手术后首次处方中阿片类药物剂量与 12 个月内继续使用阿片类药物之间的关系,同时考虑了患者特征。共有 9262 名阿片类药物初治患者接受了择期手术,其中 7219 名患者在手术后开具了阿片类药物。结果显示,17%的患者在手术后一年内至少接受了一次阿片类药物的续药。较高的初始阿片类药物剂量(以吗啡毫克当量[MME]衡量)与继续使用的可能性更大相关。与接受少于 90 MME 剂量的患者相比,接受剂量大于 90 MME 的患者接受续药的可能性高 1.57 倍(95%置信区间:1.30-1.90, < 0.001)。此外,术前或术后有疼痛的患者更有可能接受阿片类药物的续药。中度或重度疼痛的患者接受续药的可能性高 1.66 倍(95%置信区间:1.45-1.91, < 0.001)。这些发现强调了在开具阿片类药物时需要考虑手术相关因素的必要性,以及制定策略来平衡优化疼痛管理与阿片类药物相关危害风险的重要性。